{"id":"NCT00711646","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.","officialTitle":"A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-06","primaryCompletion":"2004-03","completion":"2004-03","firstPosted":"2008-07-09","resultsPosted":"2012-09-14","lastUpdate":"2023-05-06"},"enrollment":189,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Spasticity","Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Sativex®","otherNames":["GW-1000-02"]},{"type":"DRUG","name":"Placebo","otherNames":["GW-4001-01"]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.","primaryOutcome":{"measure":"Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score.","timeFrame":"0-52 days","effectByArm":[{"arm":"Sativex","deltaMin":-1.18,"sd":1.83},{"arm":"Placebo","deltaMin":-0.63,"sd":1.62}],"pValues":[{"comp":"OG000 vs OG001","p":"0.048"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":19},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["17355549","25475413"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":124},"commonTop":["Dizziness","Urinary Tract Infection NOS","Fatigue","Dry Mouth","Nausea"]}}